Loading...
Oncolys BioPharma Inc.
4588.T•JPX
Healthcare
Biotechnology
¥592.00
¥11.00(1.89%)
Oncolys BioPharma Inc. (4588.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Oncolys BioPharma Inc. (4588.T), covering cash flow, earnings, and balance sheets.
Revenue Growth
-50.21%
↓ 50.21%
Operating Income Growth
12.88%
↑ 12.88%
Net Income Growth
13.09%
↑ 13.09%
Operating Cash Flow Growth
-51.10%
↓ 51.10%
Operating Margin
-6652.22%
↓ 6652.22%
Gross Margin
99.97%
↑ 99.97%
Net Profit Margin
-6793.90%
↓ 6793.90%
ROE
-105.65%
↓ 105.65%
ROIC
-98.93%
↓ 98.93%
Oncolys BioPharma Inc. (4588.T) Income Statement & Financial Overview
Analyze Oncolys BioPharma Inc.’s 4588.T earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $31.38M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $31.38M | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $1.00 | $0.00 |
| R&D Expenses | $298.23M | $266.80M | $301.83M | $222.14M |
| SG&A Expenses | $454.20M | $437.86M | $144.05M | $156.73M |
| Operating Expenses | $451.26M | $436.77M | $445.88M | $378.87M |
| Total Costs & Expenses | $451.26M | $436.77M | $445.88M | $378.87M |
| Interest Income | $0.00 | $0.00 | $529000.00 | $518000.00 |
| Interest Expense | $0.00 | $0.00 | $1.04M | $1.14M |
| Depreciation & Amortization | $435000.00 | $571500.00 | $25.84M | $571500.00 |
| EBITDA | -$453.99M | -$437.29M | -$388.66M | -$362.15M |
| EBITDA Ratio | -$12.38 | |||
| Operating Income | -$451.26M | -$436.77M | -$414.50M | -$378.87M |
| Operating Income Ratio | -$13.21 | |||
| Other Income/Expenses (Net) | $14.12M | -$54.10M | $24.79M | $15.58M |
| Income Before Tax | -$437.15M | -$490.87M | -$389.70M | -$363.29M |
| Income Before Tax Ratio | -$12.42 | |||
| Income Tax Expense | $938000.00 | $954000.00 | $931000.00 | $940000.00 |
| Net Income | -$438.09M | -$491.82M | -$390.63M | -$364.23M |
| Net Income Ratio | -$12.45 | |||
| EPS | -$17.86 | -$22.40 | -$18.72 | -$18.24 |
| Diluted EPS | -$17.86 | -$22.40 | -$18.72 | -$18.24 |
| Weighted Avg Shares Outstanding | $24.53M | $21.96M | $20.87M | $19.97M |
| Weighted Avg Shares Outstanding (Diluted) | $24.53M | $21.96M | $20.87M | $19.97M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan